more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Maryland Biotech Gains Regulatory Approval

Research Report
  ()
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients.
Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs License Agreement With Boston Medical Center

Research Report
  ()
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

FDA Expedites Review of Gene Therapy Co.'s Drug

  ()
Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold.
Tags: Biotechnology / Pharmaceuticals

Biopharma Using AI to Find Promising Cancer Drug Candidates

  ()
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development.
Tags: Biotechnology / Pharmaceuticals

New Data Supports BLA Package

Research Report
  ()
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says

  ()
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company.
Tags: Biotechnology / Pharmaceuticals

California Biopharma Shows Promising Phase 1 Data

Research Report
  ()
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

FDA Decision on Drug for Bone Marrow Due Early 2025

Research Report
  ()
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Drug Trial Shows Positive Interim Results for ALS Treatment

  ()
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others.
Tags: Biotechnology / Pharmaceuticals

Approval Sought in Japan for New Drug to Lower Cholesterol

Research Report
  ()
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

  ()
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

Is This California Biopharma Co. In the Right Place at the Right Time?

Research Report
  ()
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies.
Tags: Biotechnology / Pharmaceuticals

Biotech Initiates Phase III Trial for Heart Disease Drug

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.
Tags: Biotechnology / Pharmaceuticals

Analyst Says Biotech's Data Supports Advancement Into Phase III

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
Tags: Biotechnology / Pharmaceuticals

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

  ()
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.
Tags: Biotechnology / Pharmaceuticals

Pharma Stock Has Significant Upside Potential, Analyst Says

Research Report
  ()
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Shares Positive Phase I Data for Alzheimer's Treatment

Research Report
  ()
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 51 to 67 of 67 Prev